The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Outcomes and patterns of relapse of NPM1-mutated AML treated with venetoclax-based therapies
In this video, Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, The University of Texas MD Anderson Cancer Center, Houston, TX, presents an analysis of outcomes and patterns of relapse in patients with NPM1-mutated acute myeloid leukemia (AML) treated with venetoclax-based regimens of varying intensities. Dr Jen suggests that venetoclax-based therapies are likely effective at eradicating NPM1-mutated leukemia, and that relapses may often arise from a different clone. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
